Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Janux Therapeutics
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 07, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Announces Updates to Board of Directors
July 22, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 08, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
February 29, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
February 26, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
February 20, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
January 08, 2024
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 07, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
July 17, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
June 05, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 09, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
April 24, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
April 20, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 10, 2023
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
June 02, 2022
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
April 26, 2022
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
July 19, 2021
From
Janux Therapeutics
Via
Business Wire
Tickers
JANX
Janux Therapeutics Appoints Dr. Wayne Godfrey as Chief Medical Officer
June 03, 2021
From
Janux Therapeutics
Via
Business Wire
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
April 20, 2021
From
Janux Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.